Sanofi’s third Translate collaboration sees big bucks at last
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
Germany stakes its claim over Curevac
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
New Genmab/Abbvie tie-up rings old bells
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
Genmab brings on Abbvie for bispecific boost
Abbvie pays handsomely to join the CD20 bispecific brawl, handing over $750m to Genmab for access to a project that trails the competition.
Astrazeneca wants Gilead; or does it?
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
Gilead opts not to buy Arcus
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
Merck joins Covid-19 pack with vaccine and antiviral deals
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Added firepower could signal a spending spree for Sanofi
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
Astrazeneca moves to upstage Moderna in Covid-19 vaccines
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
